You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Low-Grade B-cell Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

Withdrawn
  • Leukemia
  • Stem Cell Transplantation
  • Munich, Bavaria, Germany
    3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

B-cell Malignancy, Low-grade, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma Trial in China (BGB-16673)

Recruiting
  • B-cell Malignancy, Low-grade
  • +4 more
  • Beijing, Beijing, China
  • +8 more
Jul 20, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

Low-Grade B-cell Lymphoma Trial in New York (rhuFlt3L/CDX-301, Poly-ICLC)

Recruiting
  • Low-Grade B-cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Nov 17, 2020

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL) Trial in Baltimore

Completed
Has Results
  • CD20+, B-cell Lymphomas
  • +5 more
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oct 4, 2021

Non-Hodgkin's Lymphoma Trial in United States (Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab)

Terminated
Has Results
  • Non-Hodgkin's Lymphoma
  • Berkeley, California
  • +8 more
Sep 6, 2021

Phase 1, NSCLC, SCLC Trial in United States (Oral MRT-2359)

Recruiting
  • NSCLC
  • +6 more
  • Oral MRT-2359
  • Scottsdale, Arizona
  • +7 more
Dec 20, 2022

B-cell Lymphoma Trial in United States (SD-101, Radiation therapy)

Terminated
Has Results
  • B-cell Lymphoma
  • Stanford, California
  • +4 more
Aug 20, 2020

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Not yet recruiting
  • Lymphoma, B-Cell
  • +6 more
  • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
  • Guayaquil, Guayas, Ecuador
    Instituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in United States (veltuzumab)

Completed
  • NHL
  • +17 more
  • veltuzumab
  • Savannah, Georgia
  • +4 more
Aug 12, 2021

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular

Recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • +8 more
    • Boston, Massachusetts
    • +6 more
    Apr 14, 2022

    Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    • +8 more
    • Biospecimen Collection
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Mar 8, 2023

    B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

    Recruiting
    • B Cell Lymphoma
    • +5 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 3, 2023

    NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis, Saint Louis (FT596, Rituximab)

    Suspended
    • NHL
    • +3 more
    • Minneapolis, Minnesota
    • +1 more
    Jan 31, 2023

    Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

    Not yet recruiting
    • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
    • +21 more
    • Biopsy
    • +8 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Apr 7, 2023

    Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

    Available
    • Large B-cell Lymphoma
    • +4 more
    • Epcoritamab
    • (no location specified)
    Feb 16, 2023

    Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

    Not yet recruiting
    • Lymphoma, B-Cell
    • +7 more
    • Adaptive Bridging Radiation Therapy (ABRT)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Aug 16, 2023

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022